Literature DB >> 19437440

Fragmin/protamine microparticles as cell carriers to enhance viability of adipose-derived stromal cells and their subsequent effect on in vivo neovascularization.

Shingo Nakamura1, Satoko Kishimoto, Shin-ichiro Nakamura, Masaki Nambu, Masanori Fujita, Yoshihiro Tanaka, Yasutaka Mori, Masahiro Tagawa, Tadaaki Maehara, Masayuki Ishihara.   

Abstract

We prepared fragmin/protamine microparticles (F/P MPs) as cell carriers to enhance cell viability. Use of material consisting of a low-molecular-weight heparin (fragmin) mixed with protamine resulted in water-insoluble microparticles (about 0.5-1 microm in diameter). In this study, we investigated the capability of F/P MPs to enhance the viabilities of human microvascular endothelial cells (HMVECs), human dermal fibroblasts (fibroblasts), and adipose tissue-derived stromal cells (ATSCs) in suspension culture. F/P MPs were bound to the surfaces of these cells, and the interaction of these cells with F/P MPs induced cells/F/P MPs-aggregate formations in vitro, and maintained viabilities of those cells for at least 3 days. The ATSCs/F/P MPs-aggregates adhered to and grew on suspension culture plates in a fashion similar to those on type I collagen-coated plates. The cultured ATSCs secreted significant amounts of angiogenic heparin-binding growth factors such as FGF-2. When the ATSCs/F/P MPs-aggregates were subcutaneously injected into the back of nude mice, significant neovascularization and fibrous tissue formation were induced near the site of injection from day 3 to week 2. The ATSCs/F/P MPs-aggregates were thus useful and convenient biomaterials for cell-therapy of angiogenesis. (c) 2009 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19437440     DOI: 10.1002/jbm.a.32506

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  10 in total

1.  Three-dimensional culture using human plasma-medium gel with fragmin/protamine microparticles for proliferation of various human cells.

Authors:  Satoko Kishimoto; Masayuki Ishihara; Makoto Takikawa; Megumi Takikawa; Yuki Sumi; Shingo Nakamura; Masanori Fujita; Toshinori Sato; Tomoharu Kiyosawa
Journal:  Cytotechnology       Date:  2013-08-17       Impact factor: 2.058

2.  Delivery system for autologous growth factors fabricated with low-molecular-weight heparin and protamine to attenuate ischemic hind-limb loss in a mouse model.

Authors:  Shingo Nakamura; Megumi Takikawa; Masayuki Ishihara; Takefumi Nakayama; Satoko Kishimoto; Susumu Isoda; Yuichi Ozeki; Masahiro Sato; Tadaaki Maehara
Journal:  J Artif Organs       Date:  2012-08-14       Impact factor: 1.731

3.  Attenuation of limb loss in an experimentally induced hindlimb ischemic model by fibroblast growth factor-2/fragmin/protamine microparticles as a delivery system.

Authors:  Shingo Nakamura; Masayuki Ishihara; Megumi Takikawa; Satoko Kishimoto; Susumu Isoda; Masanori Fujita; Masahiro Sato; Tadaaki Maehara
Journal:  Tissue Eng Part A       Date:  2012-08-16       Impact factor: 3.845

Review 4.  Biomedical application of low molecular weight heparin/protamine nano/micro particles as cell- and growth factor-carriers and coating matrix.

Authors:  Masayuki Ishihara; Satoko Kishimoto; Makoto Takikawa; Hidemi Hattori; Shingo Nakamura; Masafumi Shimizu
Journal:  Int J Mol Sci       Date:  2015-05-22       Impact factor: 5.923

5.  Autologous and heterotopic transplantation of adipose stromal vascular fraction ameliorates stress urinary incontinence in rats with simulated childbirth trauma.

Authors:  Ken-Ichi Inoue; Satoko Kishimoto; Kanya Kaga; Miki Fuse; Akira Furuta; Tomonori Yamanishi
Journal:  Regen Ther       Date:  2017-12-22       Impact factor: 3.419

Review 6.  Recent Progress on Heparin-Protamine Particles for Biomedical Application.

Authors:  Yuuki Hata; Hiromi Miyazaki; Masayuki Ishihara; Shingo Nakamura
Journal:  Polymers (Basel)       Date:  2022-02-25       Impact factor: 4.329

7.  Three-dimensional expansion using plasma-medium gel with fragmin/protamine nanoparticles and fgf-2 to stimulate adipose-derived stromal cells and bone marrow-derived mesenchymal stem cells.

Authors:  Satoko Kishimoto; Masayuki Ishihara; Yasutaka Mori; Megumi Takikawa; Yuki Sumi; Shingo Nakamura; Toshinori Sato; Tomoharu Kiyosawa
Journal:  Biores Open Access       Date:  2012-12

8.  Novel experimental and clinical therapeutic uses of low-molecular-weight heparin/protamine microparticles.

Authors:  Satoko Kishimoto; Masayuki Ishihara; Megumi Takikawa; Yasutaka Mori; Hidemi Hattori; Masanori Fujita; Shingo Nakamura
Journal:  Pharmaceutics       Date:  2012-01-11       Impact factor: 6.321

Review 9.  Applications and implications of heparin and protamine in tissue engineering and regenerative medicine.

Authors:  Judee Grace E Nemeno; Soojung Lee; Wojong Yang; Kyung Mi Lee; Jeong Ik Lee
Journal:  Biomed Res Int       Date:  2014-06-03       Impact factor: 3.411

Review 10.  Heparinoid Complex-Based Heparin-Binding Cytokines and Cell Delivery Carriers.

Authors:  Masayuki Ishihara; Shingo Nakamura; Yoko Sato; Tomohiro Takayama; Koichi Fukuda; Masanori Fujita; Kaoru Murakami; Hidetaka Yokoe
Journal:  Molecules       Date:  2019-12-17       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.